Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

21.72 +0.30 (+1.40%)

Streaming Delayed Price Updated: 12:17 PM EST, Feb 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Apellis Pharma Shares Jump As FDA Accepts Its Lead Product Application For Eye Disease ↗

November 18, 2022

Via Benzinga

Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment ↗

November 18, 2022

The delay is at Apellis' behest. The company wanted to include updated data in its request.

Via Investor's Business Daily

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 18, 2022

Via Benzinga

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

November 18, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

November 17, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Why Are Apellis Pharmaceuticals Shares Falling Today? ↗

November 04, 2022

Via Benzinga

Where Apellis Pharmaceuticals Stands With Analysts ↗

September 08, 2022

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022 ↗

November 10, 2022

Upgrades

Via Benzinga

5 Analysts Have This to Say About Apellis Pharmaceuticals ↗

November 08, 2022

Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:APLS) within the last quarter:

Via Benzinga

Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 07, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Yelp, Twilio, Atlassian, And Other Big Losers From Friday ↗

November 07, 2022

U.S. stocks closed higher on Friday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 04, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio ↗

November 04, 2022

Apellis long said it wouldn't wait for 24-month data for its eye drug. Apellis was wrong.

Via Investor's Business Daily

Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday ↗

November 07, 2022

Gainers

Via Benzinga

Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session ↗

November 04, 2022

Gainers

Via Benzinga

Why Starbucks Shares Are Trading Higher; Here Are 43 Stocks Moving Premarket ↗

November 04, 2022

Gainers Sentage Holdings Inc. (NASDAQ: SNTG) shares rose 67.7% to $5.10 in pre-market trading after jumping 24% on Thursday.

Via Benzinga

Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)

November 03, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis to Present New Long-Term Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) in PNH Patients at 2022 ASH Annual Meeting

November 03, 2022

Robust improvements in key markers of disease sustained across a broad population of adults with paroxysmal nocturnal hemoglobinuria (PNH)

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results

October 31, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

7 Analysts Have This to Say About Apellis Pharmaceuticals ↗

October 18, 2022

Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 07, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

October 04, 2022

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per...

Via Benzinga

Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

October 04, 2022

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

Via MarketBeat

Topics Stocks

Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session ↗

October 03, 2022

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.

Via Benzinga

Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today ↗

October 03, 2022

Both companies presented data at the American Academy of Ophthalmology meeting.

Via Investor's Business Daily

Investigator Says Apellis' Lead Product Shows 'First Direct Evidence Of Slowing Geographic Atrophy Lesion Growth' ↗

October 03, 2022

Via Benzinga

Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

September 30, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting

September 30, 2022

From Apellis Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

September 29, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.